Sponsored by
This is probably the most important article about Optune. It updates the data reported the prior year and shows a little better results. If you can maintain over 90% compliance, the % of patients alive at 5 years was 29.3% compared to 4.5% in the control group which was Temodar and whatever else the doctor and patient wanted to use. This is the best survival rate ever reported in a large brain tumor trial and should finally put to rest any resistance to it's use. At this point, Optune (plus Temodar) should be considered the new standard of care.